Reliability of the MDi Psoriasis® Application to Aid Therapeutic Decision-Making in Psoriasis.

dc.contributor.authorMoreno-Ramírez, D
dc.contributor.authorHerrerías-Esteban, J M
dc.contributor.authorOjeda-Vila, T
dc.contributor.authorCarrascosa, J M
dc.contributor.authorCarretero, G
dc.contributor.authorde la Cueva, P
dc.contributor.authorFerrándiz, C
dc.contributor.authorGalán, M
dc.contributor.authorRivera, R
dc.contributor.authorRodríguez-Fernández, L
dc.contributor.authorRuiz-Villaverde, R
dc.contributor.authorFerrándiz, L
dc.date.accessioned2025-01-07T12:39:00Z
dc.date.available2025-01-07T12:39:00Z
dc.date.issued2017-04-04
dc.description.abstractTherapeutic decisions in psoriasis are influenced by disease factors (e.g., severity or location), comorbidity, and demographic and clinical features. We aimed to assess the reliability of a mobile telephone application (MDi-Psoriasis) designed to help the dermatologist make decisions on how to treat patients with moderate to severe psoriasis. We analyzed interobserver agreement between the advice given by an expert panel and the recommendations of the MDi-Psoriasis application in 10 complex cases of moderate to severe psoriasis. The experts were asked their opinion on which treatments were most appropriate, possible, or inappropriate. Data from the same 10 cases were entered into the MDi-Psoriasis application. Agreement was analyzed in 3 ways: paired interobserver concordance (Cohen's κ), multiple interobserver concordance (Fleiss's κ), and percent agreement between recommendations. The mean percent agreement between the total of 1210 observations was 51.3% (95% CI, 48.5-54.1%). Cohen's κ statistic was 0.29 and Fleiss's κ was 0.28. Mean agreement between pairs of human observers only, excluding the MDi-Psoriasis recommendations, was 50.5% (95% CI, 47.6-53.5%). Paired agreement between the recommendations of the MDi-Psoriasis tool and the majority opinion of the expert panel (Cohen's κ) was 0.44 (68.2% agreement). The MDi-Psoriasis tool can generate recommendations that are comparable to those of experts in psoriasis.
dc.identifier.doi10.1016/j.ad.2017.02.009
dc.identifier.essn1578-2190
dc.identifier.pmid28385425
dc.identifier.urihttps://hdl.handle.net/10668/24818
dc.issue.number7
dc.journal.titleActas dermo-sifiliograficas
dc.journal.titleabbreviationActas Dermosifiliogr
dc.language.isoen
dc.language.isoes
dc.organizationSAS - Hospital de Poniente
dc.page.number650-656
dc.pubmedtypeComparative Study
dc.pubmedtypeEvaluation Study
dc.pubmedtypeJournal Article
dc.subjectApps
dc.subjectBiologics
dc.subjectBiológicos
dc.subjectComorbidity
dc.subjectComorbilidad
dc.subjectHealth applications
dc.subjectPsoriasis
dc.subjectReproducibilidad
dc.subjectReproducibility
dc.subjecteHealth
dc.subjecteSalud
dc.subject.meshAdult
dc.subject.meshCell Phone
dc.subject.meshClinical Decision-Making
dc.subject.meshContraindications, Drug
dc.subject.meshCross-Sectional Studies
dc.subject.meshDermatologic Agents
dc.subject.meshDermatology
dc.subject.meshExpert Testimony
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshMobile Applications
dc.subject.meshObserver Variation
dc.subject.meshPUVA Therapy
dc.subject.meshPsoriasis
dc.subject.meshReproducibility of Results
dc.subject.meshUltraviolet Therapy
dc.titleReliability of the MDi Psoriasis® Application to Aid Therapeutic Decision-Making in Psoriasis.
dc.title.alternativeFiabilidad de una aplicación de ayuda a la toma de decisiones terapéuticas en el paciente con psoriasis (MDi Psoriasis®).
dc.typeresearch article
dc.volume.number108

Files